Zimmer Biomet Holdings (NYSE:ZBH) Q1 Earnings Rise, Revises 2025 Revenue Guidance Upward

Zimmer Biomet Holdings (NYSE:ZBH) recently reported solid financial performance, with increased sales and net income for the first quarter of 2025, along with a raised earnings guidance for the year. Despite these positive results, the company's stock price fell 11% over the past week. This decline came amid a broader market downturn, with stocks slipping as investors awaited news on tariffs and Federal Reserve decisions. While Zimmer Biomet's financial updates were strong, they were not enough to counteract the overall market's concerns and trends, which weighed heavily on the stock.

We've identified 1 warning sign with Zimmer Biomet Holdings and understanding the impact should be part of your investment process.

Find companies with promising cash flow potential yet trading below their fair value.

The recent 11% decline in Zimmer Biomet Holdings’ stock, despite solid Q1 2025 financial performance and optimistic earnings guidance, underscores the broader market influences over individual company achievements. The company reported robust revenue of US$7.70 billion and earnings of US$913.40 million, yet these improvements couldn't shield its share price from broader economic concerns regarding tariffs and Federal Reserve decisions. Over the past five years, however, Zimmer Biomet's total shareholder return, including dividends, shrank by 17.84%, highlighting challenges in maintaining longer-term growth.

In comparison to the past year, the company underperformed both the US Medical Equipment industry and the US market, which saw gains of 8.1% and 9.3%, respectively. The recent developments, including the acquisition of Paragon 28 and upcoming product launches, could enhance revenue opportunities in key markets like foot and ankle segments. Analysts expect revenue growth of 3.9% annually over the next three years, with earnings anticipated to reach US$1.4 billion by 2028. However, execution risks from the Paragon 28 integration and an unpredictable operational environment could pose challenges.

Considering these projections, the current share price of US$102.79 remains below the analyst consensus price target of US$117.85, suggesting a potential upside. However, realizing this target is contingent on fulfilling growth assumptions and effectively managing operational risks. Investors should weigh these forecasts and challenges when considering Zimmer Biomet’s potential trajectory.

Examine Zimmer Biomet Holdings' past performance report to understand how it has performed in prior years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com